Skip to search formSkip to main contentSkip to account menu

Carboplatin

Known as: CBDCA, cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II), (SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinum 
A second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Highly Cited
2010
Highly Cited
2009
Highly Cited
2009
BACKGROUND Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in… 
Highly Cited
2006
Highly Cited
2006
BACKGROUND Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with… 
Highly Cited
2004
Highly Cited
2004
PURPOSE To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or… 
Highly Cited
2004
Highly Cited
2004
PURPOSE Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE), an orally active epidermal… 
Highly Cited
1989
Highly Cited
1989
A dosage formula has been derived from a retrospective analysis of carboplatin pharmacokinetics in 18 patients with pretreatment…